Clinical trials: Influenza H1N1
Influenza A (H1N1)
Observational Safety and Effectiveness Study of Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Egg Derived Vaccine
This observational study will evaluate the safety and effectiveness following administration of adjuvanted Swine Origin A (H1N1) Pandemic Subunit Egg Derived Vaccine through both an ad hoc active monitoring system and a passive…
- Trial name
- NCT01101074
- Testing
- This is non-intervention observational study
- Where
- Italy
- Volunteers
- 135,469 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Pandemic Influenza A (H1N1), A New Flu Virus of Swine Origin
Observational Safety Study of Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Egg Derived Vaccine
This is an observational safety study of a prophylactic use of Flu Egg Derived Adjuvanted Swine Origin A(H1N1) Vaccine in subjects 6 months of age and older.
- Trial name
- NCT01040741
- Testing
- Non-intervention observational study
- Where
- 14 sites in Argentina, Netherlands
- Volunteers
- 7,284 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza, Swine-origin A/H1N1 Influenza
A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly
The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine in adults and the elderly. Primary Objectives: To describe the immunogenicity of the candidate vaccines after a single injection.
- Trial name
- NCT00952276
- Testing
- Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant, Monovalent Subvirion A/H1N1 influenza vaccine, Normal saline solution
- Where
- 15 sites in United States
- Volunteers
- 548 people, healthy volunteers welcome
- Sponsor
- Sanofi
H1N1 Influenza Virus
Analysis of the Results From Influenza Rapid Test A Positive and H1N1 Real Time RT-PCR
The first outbreak of a new H1N1 influenza pandemic originated in the North America in April 2009. As of July 1, 2009, a total of 77,201 cases were accumulated in 103 countries around the world and the mortality rate of was about…
- Trial name
- NCT01277380
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Taipei Medical University WanFang Hospital
Influenza A Virus, H1N1 Subtype
A Pragmatic Randomized Controlled Trial of Chinese Herbal Medicine for Severe Pandemic H1N1 Influenza
The aim of this study is to evaluate the effectiveness and safety of Chinese herbal medicines for severe pandemic H1N1 influenza.
- Trial name
- 200907001-2A (NCT01053533)
- Testing
- Chinese herbal medicines plus western therapy, western therapy
- Where
- China
- Volunteers
- 1,100 people
- Sponsor
- Beijing Ditan Hospital
Lymphoma, Multiple Myeloma
Evaluation of Influenza H1N1 Vaccine in Adults With Lymphoid Malignancies on Chemotherapy
The purpose of this study is to determine whether adults with hematologic malignancies on active systemic therapy or shortly after bone marrow transplantation need one or two doses of adjuvanted vaccine to achieve best possible…
- Conditions
- Lymphoma, Multiple Myeloma, Influenza A Virus, H1N1 Subtype
- Trial name
- NCT01016548
- Testing
- AS03-adjuvanted H1N1 pandemic influenza vaccine
- Where
- Canada
- Volunteers
- 42 people
- Sponsor
- University Health Network, Toronto
H1N1 Influenza
The Impact of Vitamin on the Clinical Course in Cases Infected by Novel H1N1 Influenza Virus A
Influenza continues to inflict an important burden on health-care systems. The 2009 H1N1 influenza virus first appeared in Mexico and the United States in March and April 2009 and has swept the globe with unprecedented speed.
- Trial name
- NCT01127282
- Testing
- Vitamin (vitamin A 15 mg,C 500 mg, E 400IU)
- Where
- South Korea
- Volunteers
- 180 people
- Sponsor
- Seoul National University Hospital
Serology Analysis, Novel H1N1 Influenza Vaccination
Antibody Titer Analysis After H1N1 Vaccination in Pediatric Haemato-oncology Patients
The patients of pediatric haemato-oncology have a higher risk for novel H1N1 influenza infection than general population, and they are strongly recommended to receive novel H1N1 vaccination.
- Conditions
- Serology Analysis, Novel H1N1 Influenza Vaccination, Pediatric Haemato-oncology Patients
- Trial name
- NCT01046227
- Testing
- Influenza A (H1N1) 2009 monovalent vaccine, inactivated
- Where
- Taiwan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Influenza, Swine-origin A/H1N1 Influenza
Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Children Aged 6 to 35 Month
The purpose of this study is to generate data on immunogenicity and safety of the monovalent H1N1 vaccine in support of the development and registration.
- Trial name
- NCT01040078
- Testing
- 7.5ug H1N1 Influenza vaccine, 15ug H1N1 vaccine, seasonal influenza vaccine
- Where
- 3 sites in China
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention, China
Influenza H1N1
Efficacy and Safety of Vaccination Against Influenza H1N1 in Patients With Inflammatory Bowel Diseases (IBD) Treated Immunomodulators and Biologics
The spread of Influenza H1N1 has prompted the development of vaccines against this virus. IBD patients are at increased risk of developing complications of Influenza H1N1.
- Trial name
- NCT01019837
- Testing
- Focetria (Monovalent MF59-Adjuvanted vaccine)
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
H1N1 Influenza
Antibody Production Following H1N1 Influenza Vaccination After Stem Cell and Heart Transplantation
Stem cell and and heart transplant patients will receive pandemic H1N1 influenza vaccination according to the clinical guidelines. In these patients the investigators will measure the specific antibody production.
- Trial name
- NCT01008683
- Where
- Israel
- Volunteers
- 300 people
- Sponsor
- Hadassah Medical Organization